.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EK01_Axitinib.Axitinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EK01_Axitinib.Axitinib| name: | Axitinib |
| ATC code: | L01EK01 | route: | oral |
| n-compartments | 2 |
Axitinib is an oral, small-molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3. It is primarily used for the treatment of advanced renal cell carcinoma and is approved for use in several countries, including the United States and the European Union.
Population pharmacokinetic analysis in adult patients with solid tumors, including renal cell carcinoma, with oral administration. Data represents a typical adult (mean weight ~70 kg) without severe hepatic or renal impairment.
Chen, Y, et al., & Pithavala, YK (2015). Axitinib plasma pharmacokinetics and ethnic differences. Investigational new drugs 33(2) 521–532. DOI:10.1007/s10637-015-0214-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/25663295
Chen, Y, et al., & Pithavala, YK (2013). Clinical pharmacology of axitinib. Clinical pharmacokinetics 52(9) 713–725. DOI:10.1007/s40262-013-0068-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23677771
Chen, Y, et al., & Hu, P (2011). A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers. International journal of clinical pharmacology and therapeutics 49(11) 679–687. DOI:10.5414/cp201570 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22011693